Section 301 Investigation: Germany Pharmaceutical Underpayment
Current understanding
The U.S. Trade Representative has initiated a Section 301 investigation into Germany’s alleged persistent underpayment for innovative pharmaceutical products, with a public hearing scheduled and a request for public comments issued. The investigation is at the initiation stage; no determination, remedy, or tariff has been imposed. Status: open — pending hearing and comment period.
Evidence log
Open questions
Related
Contributing findings
Initiation of Section 301 Investigation; Hearing; and Request for Public Comments: Germany's Persistent Underpayment for Innovative Pharmaceutical Products
24-jun-2026
novelty 3
per-area 3
introduces